Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid for Liver Cancer
This trial compares the use of gadolinium contrast-enhanced Abbreviated MRI (AMRI) to standard ultrasound for the screening and surveillance of subjects with liver cirrhosis who are at risk for developing hepatocellular carcinoma (HCC).
- Liver Cancer
- Liver Cirrhosis
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What is the capacity of individuals who may be enrolled in this medical experiment?
"Affirmative. Clinicaltrials.gov corroborates that this scientific experiment is still recruiting patients, with the original post dating back to April 27th 2018 and the most recent edit on April 6th 2022. 150 participants from 1 medical centre are needed for successful completion of this trial."
Is it currently feasible for people to join this clinical trial?
"Affirmative, according to the records on clinicaltrials.gov this investigation is actively trying to recruit patients. The trial was initially posted in April 2018 and recently updated in April 2022 with a target of 150 participants at 1 site."
Has the FDA sanctioned Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid?
"With it's Phase 4 status, our team at Power has assigned Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid a score of 3 on the safety scale. This is because the treatment is already approved for use."
Are there any other studies that have utilized Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid?
"Currently, there are 10 clinical trials occurring in regards to Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid with none of them in the third phase. Birmingham, Alabama is one of 26 cities conducting studies relating to this medication."